Table 2 Propensity score analysis comparing AOE incidence in PACE and OPTIC.

From: Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials

Safety parameter

PACE CP-CML 45 mg (n = 270)

OPTIC 45 mg→15 mg (n = 94)

Patients with AOE

61

9

   Unadjusted AOE rate (95% CI)

0.2230 (0.1733–0.2728)

0.0879 (0.0297–0.1461)

Adjusted AOE rate

   Odds ratio (95% CI)

—

0.3288 (0.1499–0.7212)

   Relative risk (95% CI)

—

0.4066 (0.2060–0.8027)

  1. AOE arterial occlusive event, CI confidence interval, CP-CML chronic-phase chronic myeloid leukemia.
Back to article page